ARWR News & Analysis

3 articles

Market Mood

2 Bullish1 Neutral0 Bearish

EarningsBullish7/27/2026

Arrowhead Pharma (ARWR) Price Target Raised to $115 After Trial Data

H.C. Wainwright has raised the price target for Arrowhead Pharmaceuticals (ARWR) to $115 based on new trial data. This adjustment comes as trial results indicate promising developments that could positively impact the company's valuation. Typically, price target revisions from analysts can affect investor sentiment and trading patterns. For ordinary investors, this increase suggests a potentially favorable market outlook for Arrowhead Pharmaceuticals going forward.

#ARWR #Earnings #Healthcare

EarningsNeutral7/23/2026

Arrowhead Pharma (ARWR) Stock Rating Reiterated by H.C. Wainwright

H.C. Wainwright has reiterated its rating for Arrowhead Pharmaceuticals (ARWR) based on recent trial data. The specifics of the trial data were not disclosed in the article, but the reaffirmation of the rating could indicate confidence in the company's pipeline. Analysts often rely on such ratings to gauge potential market performance and investor sentiment. This reaffirmation may impact investor decisions regarding ARWR, signaling stability amid ongoing trials.

#ARWR #Earnings

EarningsBullish7/22/2026

Arrowhead Pharmaceuticals Stock Jumps on Phase 3 Trial Results

Arrowhead Pharmaceuticals (ARWR) experienced a significant increase in stock price due to positive Phase 3 trial results. The Phase 3 SHASTA-3 and SHASTA-4 studies of plozasiran in patients with severe hypertriglyceridemia met their primary endpoint, with median triglyceride reductions of 79% and 81% at month 12, respectively, compared to approximately 27% with placebo. This development indicates promising advancements in their drug therapy and could have a strong impact on investor confidence and market perception of the companys potential for success. Investors should pay attention to how these results might influence ARWRs market position.

#ARWR #Earnings #Pharmaceuticals